| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
4,260,000 |
| Market
Cap: |
87.97(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.65 - $20.65 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Opiant Pharmaceuticals is a pharmaceutical company developing medicines for addictions and drug overdose. Co.'s longer term pipeline includes medicines in development for Alcohol Use Disorder, Opioid Use Disorder, and Acute Cannabinoid Overdose. Co. is also pursuing other treatment opportunities within the addiction and drug overdose field. Co. has developed NARCAN® (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
42,039 |
| Total Buy Value |
$0 |
$0 |
$0 |
$535,574 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
73,613 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,050,459 |
| Total People Sold |
0 |
0 |
0 |
7 |
| Total Sell Transactions |
0 |
0 |
0 |
28 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Collard Craig A |
Director |
– • – |
2022-06-13 |
4 |
B |
$10.94 |
$44,149 |
D/D |
4,037 |
53,822 |
2.39 |
-8% |
|
| Collard Craig A |
Director |
– • – |
2022-06-10 |
4 |
B |
$11.50 |
$19,118 |
D/D |
1,663 |
49,785 |
2.39 |
-16% |
|
| Sinclair Michael |
Director |
– • • |
2022-06-09 |
4 |
S |
$12.25 |
$96,726 |
D/D |
(7,896) |
32,836 |
|
19% |
|
| Sinclair Michael |
Director |
– • • |
2022-06-07 |
4 |
S |
$12.86 |
$10,288 |
D/D |
(800) |
40,732 |
|
22% |
|
| Sinclair Michael |
Director |
– • • |
2022-06-06 |
4 |
S |
$12.94 |
$99,483 |
D/D |
(7,688) |
41,532 |
|
24% |
|
| Sinclair Michael |
Director |
– • • |
2022-06-03 |
4 |
S |
$13.59 |
$139,488 |
D/D |
(10,264) |
49,220 |
|
23% |
|
| Sinclair Michael |
Director |
– • • |
2022-06-02 |
4 |
S |
$13.88 |
$135,136 |
D/D |
(9,736) |
59,484 |
|
25% |
|
| Gorman Brian |
General Counsel |
– – – |
2022-06-02 |
4 |
S |
$13.52 |
$15,521 |
D/D |
(1,148) |
32,438 |
|
25% |
|
| Silver Gabrielle Alison |
Director |
– • – |
2022-05-16 |
4 |
B |
$13.29 |
$33,220 |
D/D |
2,500 |
21,343 |
2.39 |
-23% |
|
| Collard Craig A |
Director |
– • – |
2022-05-16 |
4 |
B |
$13.54 |
$367,611 |
D/D |
27,150 |
48,122 |
2.39 |
-23% |
|
| Collard Craig A |
Director |
– • – |
2022-05-13 |
4 |
B |
$10.49 |
$38,698 |
D/D |
3,689 |
20,972 |
2.39 |
-16% |
|
| Macdougall Ann L. |
Director |
– • – |
2022-05-13 |
4 |
B |
$10.93 |
$32,778 |
D/D |
3,000 |
26,179 |
2.39 |
-16% |
|
| Crystal Roger |
Chief Executive Officer |
• • • |
2022-01-27 |
4 |
S |
$26.15 |
$52,169 |
D/D |
(1,995) |
78,488 |
|
51% |
|
| Skolnick Phil |
Chief Scientific Officer |
• – – |
2022-01-27 |
4 |
S |
$26.19 |
$39,756 |
D/D |
(1,518) |
22,445 |
|
51% |
|
| Otoole David D |
Chief Financial Officer |
• – – |
2022-01-10 |
4 |
S |
$30.60 |
$13,219 |
D/D |
(432) |
35,583 |
|
53% |
|
| Skolnick Phil |
Chief Scientific Officer |
• – – |
2022-01-10 |
4 |
S |
$30.49 |
$11,739 |
D/D |
(385) |
23,963 |
|
53% |
|
| Crystal Roger |
Chief Executive Officer |
• • • |
2022-01-10 |
4 |
S |
$30.49 |
$32,258 |
D/D |
(1,058) |
80,483 |
|
53% |
|
| Crystal Roger |
Chief Executive Officer |
• • • |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
81,541 |
|
- |
|
| Gorman Brian |
General Counsel |
– – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
33,586 |
|
- |
|
| Ellison Mark Jason Heath |
Chief Development Officer |
• – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
19,636 |
|
- |
|
| Ruth Matthew R. |
Chief Commercial Officer |
• – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
29,000 |
|
- |
|
| Otoole David D |
Chief Financial Officer |
• – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
36,015 |
|
- |
|
| Skolnick Phil |
Chief Scientific Officer |
• – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
24,348 |
|
- |
|
| Thomas Thomas T. |
Director |
– • – |
2021-09-22 |
4 |
AS |
$25.02 |
$18,390 |
D/D |
(735) |
10,375 |
|
6% |
|
| Thomas Thomas T. |
Director |
– • – |
2021-09-22 |
4 |
OE |
$10.00 |
$18,340 |
D/D |
1,834 |
11,110 |
|
- |
|
257 Records found
|
|
Page 3 of 11 |
|
|
